



Press release December 5<sup>th</sup>, 2018

## Follicum's diabetes project with Lund University has been awarded a Post-Doc student for 2 years for advanced studies of Follicum's peptides

**Follicum AB ("Follicum" or "Company"), a biotech company developing new peptide drugs in two areas, hair loss and diabetes, today reports that a full-time post-doc has been awarded to the diabetes project for 2 years. The aim with the project is to perform advanced experiments to further investigate the action of Follicum's different peptide classes. The post-doc will be 100% financed by the LUDC-IRC consortium.**

As previously reported Follicum is part of a large collaborative diabetes network called LUDC-IRC at Lund University. The consortium has received 100 million SEK from The Swedish Foundation of Strategic Research. The consortium has an international advisory panel that has selected 5 post-docs out of 11 to further strengthen the research. One of the post-docs has been awarded to Follicum to further strengthen the research around the role of Follicum's peptides in diabetes. The duration of the work is 2 years. A postdoctoral researcher, or post-doc, is a person professionally conducting cutting-edge research after the completion of their doctoral studies.

### **CEO Jan Alenfall comments**

*"We are very pleased to be part of the LUDC-IRC consortium and particularly pleased that a full-time post-doc has been awarded to Professor Jan Nilsson for studying Follicum's peptides in relation to diabetes. The contribution by the post-doc will significantly enhance the understanding of the potential of the peptides in diabetes and will also help to develop this project further. The work will significantly expedite our development and will increase the value of the project. The post-doc will be recruited on an international basis during Q1/Q2 2019 and the work is expected to be completed during 2021. "*

### **For further information, please contact:**

Jan Alenfall – CEO, Follicum AB  
Telephone: +46 46 19 21 97  
Email: [info@follicum.com](mailto:info@follicum.com)

*This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 5<sup>th</sup> of December 2018.*

---

### **About Follicum AB**

Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicum's research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. [www.follicum.com](http://www.follicum.com).

### **About Lund University Diabetes Centre (LUDC)**

Lund University Diabetes Centre, LUDC, is a consortium of research groups at Lund University dedicated to unravelling the pathogenesis and treatment of diabetes mellitus. <https://www.ludc.lu.se>